A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients

Not Applicable

Completed

• Conditions: HIV Infections; Histoplasmosis

• Registration Number: NCT00002438
• Lead Sponsor: Janssen, LP

Brief Summary

To assess the safety and efficacy of itraconazole versus placebo for prevention of histoplasmosis in HIV-infected patients with CD4 counts \< 150 cells/mm3 who reside where histoplasmosis is endemic. To assess the safety and efficacy of itraconazole for preventing other debilitating fungal infections, such as cryptococcosis, aspergillosis, recalcitrant oropharyngeal or vaginal candidiasis, and recurrent esophageal candidiasis.

Detailed Description

Not available

Study Timeline

• Status Verified: 1996-04
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (7)

Infectious Diseases Research Clinic / Indiana Univ Hosp; 🇺🇸 Indianapolis, Indiana, United States

Infectious Diseases of Indianapolis; 🇺🇸 Indianapolis, Indiana, United States

Infectious Diseases Association / Research Med Ctr; 🇺🇸 Kansas City, Missouri, United States

ASCC; 🇺🇸 Memphis, Tennessee, United States

Univ of Missouri at Kansas City School of Medicine; 🇺🇸 Kansas City, Missouri, United States

Dr Michael Threikeld; 🇺🇸 Memphis, Tennessee, United States

Dr Mark A Pierce; 🇺🇸 Nashville, Tennessee, United States